. 2013 Jul 18;4(6):502–513. doi: 10.7150/jca.6503

Table 1.

Baseline characteristics among three groups (group A, B and C).

	Group A (n=129)	Group B (n=62)	Group C (n=284)	P-value A vs. B	P-value A vs. C
Gender (male/female)	104/25	42/20	194/90	0.068^a	0.013^a
Age (years)	68.6±8.8	57.7±12.3	69.1±7.8	<0.001^b	0.559^b
Hepatectomy
Anatomical/non-anatomical	73/56	30/32	98/186	0.351^a	<0.001^a
HCC stage (I/II/III/IV)	8/74/39/8	5/37/19/1	26/164/76/18	0.565^a	0.724^a
Presence of LC (yes/no)	46/83	35/27	181/103	0.008^a	<0.001^a
Tumor number (single/multiple)	84/45	44/18	186/98	0.511^a	>0.999^a
Maximum tumor size (cm)	5.5±3.2	4.0±2.2	4.1±2.3	0.001^b	<0.001^b
Body mass index (kg/m²)	24.1±4.0	22.5±3.7	22.8±3.6	0.008^b	0.002^b
Diabetes mellitus (yes/no)	63/66	7/55	79/204	<0.001^a	<0.001^a
AST (IU/l)	62.9±52.1	49.9±43.5	55.7±32.9	0.092^b	0.093^b
ALT (IU/l)	53.4±39.1	54.1±69.5	52.2±42.8	0.931^b	0.795^b
ALP (IU/l)	347.9±174.8	299.0±133.3	335.9±147.6	0.053^b	0.469^b
GGT (IU/l)	150.9±174.7	105.4±193.8	89.4±84.4	0.106^b	<0.001^b
Serum albumin (g/dl)	4.00±0.49	4.04±0.39	3.75±0.49	0.555^b	<0.001^b
Total bilirubin (mg/dl)	0.82±0.41	0.86±0.48	0.85±0.40	0.607^b	0.516^b
Prothrombin time (%)	91.5±15.8	89.7±16.9	87.1±13.2	0.472^b	0.004^b
Platelets (×10⁴/mm³)	17.2±7.9	13.7±8.5	12.8±5.6	0.005^b	<0.001^b
AFP (ng/ml)	1726.1±11663.8	2450.1±7702.4	2470.3±12094.2	0.610^b	0.558^b
DCP (mAU/ml)	8573.2±45695.6	2913.2±13229.8	3330.9±14306.1	0.196^b	0.204^b
HCC histology
Well/moderate/poorly/necrosis	10/76/42/1	4/24/25/9	24/137/102/21	<0.001^a	0.021^a
Fibrous capsule (yes/no)	94/35	53/9	245/39	0.066^a	0.001^a
Microscopic vascular invasion (yes/no)	55/74	25/37	92/192	0.876^a	0.047^a
Microscopic surgical margin (yes/no)	31/98	14/48	78/206	0.858^a	0.473^a

HCC: hepatocellular carcinoma; LC: liver cirrhosis; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; GGT: gamma glutamyl transpeptidase; AFP: alpha-fetoprotein; DCP: des-γ-carboxy prothrombin; ^aFisher^,s exact test; ^bunpaired t-test.